Pancreatic cancer risk factors
Jump to navigation
Jump to search
|
Pancreatic cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pancreatic cancer risk factors On the Web |
|
American Roentgen Ray Society Images of Pancreatic cancer risk factors |
|
Risk calculators and risk factors for Pancreatic cancer risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Aravind Reddy Kothagadi M.B.B.S[3]
Overview
Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of pancreatic neoplasms.[1] Its risk factors fall into three groups: modifiable lifestyle and metabolic factors, non-modifiable demographic factors, and inherited (germline) susceptibility. Most individual factors carry only a modest relative risk. The factors with the most clinical leverage are:
- Cigarette smoking, the dominant modifiable cause (~20% of cases).
- New-onset diabetes mellitus in older adults, which often reflects occult PDAC rather than causing it.
- High-penetrance hereditary syndromes.[2][1]
Approximately 5–10% of unselected patients with PDAC carry a pathogenic germline variant. At least half of these carriers have no suggestive family history, which is the rationale for universal germline testing of all patients with PDAC.[3][4]
Risk Factors
Lifestyle and Metabolic Risk Factors
| Risk factor | Key clinical points |
|---|---|
| Cigarette smoking | Leading modifiable cause, attributable to ~20% (range 11–32%) of PDAC. Clear dose–response. Risk falls after cessation and approaches baseline ~20 years after quitting.[2][1] |
| Heavy alcohol use (≥3 drinks/day, ~30 g/day) | Higher intake carries higher risk. The effect is partly mediated through pancreatitis and acetaldehyde-related DNA damage. Independent causal evidence remains modest because of confounding by smoking.[1][4][5] |
| Obesity (BMI ≥30 kg/m²) | Independent of diabetes. Central adiposity, insulin resistance, and chronic inflammation are the proposed mechanisms.[4][6] |
| Metabolic syndrome | Risk rises with the number of components. Excess risk attenuates after recovery from metabolic syndrome.[2] |
| Long-standing type 2 diabetes (>3 years) | A modest causal risk factor. Distinct from new-onset diabetes (see below).[3][2] |
Diabetes Mellitus and New-Onset Diabetes
- Diabetes and PDAC are related in both directions. Long-standing type 2 diabetes is a modest causal factor. In contrast, new-onset diabetes (NOD) within ~3 years before diagnosis is increasingly viewed as a paraneoplastic manifestation of occult PDAC.[2][6]
- Up to ~50% of patients have diabetes at the time of PDAC diagnosis. PDAC incidence is elevated for years before diagnosis, and the association is strongest within 1 year of diabetes onset (adjusted HR ~9).[7]
- Absolute 3-year PDAC risk after NOD in adults ≥50 years is below 1%. This is too low to justify imaging every patient with NOD, but high enough to justify phenotype-based enrichment.[6]
- Features that raise risk within NOD:[6]
- Older age
- Unintentional weight loss
- Rapidly escalating glycemia
- The ENDPAC (Enriching New-Onset Diabetes for Pancreatic Cancer) model uses age, weight change, and glucose change. A score ≥3 identified a subgroup with ~1.2% annual PDAC incidence.[6]
- Post-pancreatitis diabetes mellitus carries higher PDAC risk than type 2 diabetes alone (~6.9-fold vs type 2 diabetes).[8]
Pancreatitis
Non-Modifiable Demographic Risk Factors
- Age is the dominant non-modifiable factor. Incidence rises steeply after age 50 and peaks at 70–79 years.[4]
- Male sex carries modestly higher incidence than female sex.[4]
- Race/ethnicity: In the United States, incidence is highest among non-Hispanic Black individuals, followed by White, Hispanic, and Asian–Pacific Islander populations.[3][4]
- Ashkenazi Jewish ancestry:
- Elevated risk reflects largely a higher prevalence of founder BRCA1/BRCA2 variants.[10]
- In a prospective cohort of 49,410 men, Ashkenazi Jewish heritage alone showed only a trend toward higher risk (HR 1.29; 95% CI 0.94–1.77).
- Risk was markedly elevated among Ashkenazi Jewish men with a family history of breast cancer (HR 2.61) or colorectal cancer (HR 1.92).[11]
- Non-O ABO blood group is a reproducible, modest risk factor (OR ~1.3–1.7 vs group O; adjusted OR 1.37 in a population-based case–control study). The association is stronger in people aged ≤70 years.[12][13]
Inherited (Germline) Susceptibility
- Approximately 5–10% of unselected patients with PDAC carry a pathogenic or likely pathogenic germline variant, most often in DNA damage-repair or homologous recombination genes.[3][4]
- At least half of carriers report no family history and do not meet classic syndrome criteria.[3][14]
| Gene (syndrome) | Clinical notes |
|---|---|
| STK11 (Peutz-Jeghers syndrome) | Highest-penetrance PDAC gene |
| PRSS1 (hereditary pancreatitis) | Risk mediated by recurrent pancreatic inflammation. Lifetime risk estimates have been revised downward (see below). |
| CDKN2A (familial atypical multiple mole melanoma syndrome, FAMMM) | Concurrent melanoma risk |
| BRCA2 | Most common identifiable germline variant in PDAC. Relevant to PARP inhibitor and platinum therapy. |
| PALB2 | Homologous recombination repair gene |
| BRCA1 | Lower risk than BRCA2 |
| ATM | Moderate penetrance |
| Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) | Microsatellite instability-high/mismatch repair-deficient tumors; sensitive to checkpoint inhibitors |
| TP53 (Li-Fraumeni syndrome) | Multi-organ cancer predisposition |
| APC (familial adenomatous polyposis, including the Gardner variant) | Weak association |
Estimates are compiled from guideline and review sources.[15][16][17][3]
- Hereditary pancreatitis lifetime risk: Older teaching cited lifetime PDAC risk as high as ~40–70%. More recent evidence suggests a lifetime risk below 10%, although relative risk remains very high.[3]
- Familial pancreatic cancer (FPC) is defined as ≥2 affected first-degree relatives without an identified syndrome. It accounts for ~10% of cases.[15][4]
- In FPC, relative risk rises with the number and age of affected relatives:
- In a prospective cohort, a family history of pancreatic cancer in a first-degree relative conferred an HR of 2.79 (95% CI 1.28–6.07).[11]
Early-Onset Pancreatic Cancer
- Early-onset GI cancer is typically defined as diagnosis before age 50.[19] Some pancreatic cancer consortia instead define early-onset as before age 60 and very-early-onset as before age 45.[20]
- Established risk factors are more strongly associated with earlier-onset disease than with later-onset disease. These include smoking, obesity, diabetes, tall height, and non-O blood group.
- Carrying 3–5 of these factors conferred an HR of 9.24 in people aged ≤60 years, versus 1.46 in those aged >70 years.[13]
- Alcohol intake >26 g/day (≈2 drinks) was associated with early-onset PDAC (OR 1.49), especially before age 45 (OR 2.18).[20]
- Approximately 15–30% of early-onset GI cancers carry pathogenic germline variants, for example in BRCA1/2 or mismatch repair genes. All patients with early-onset GI cancer should therefore undergo genetic testing.[19]
Factors With Uncertain or Disputed Association
- Helicobacter pylori — evidence is inconsistent:
- A case–control study linked CagA-negative H. pylori seropositivity with increased risk (OR 1.68).[12]
- A nested analysis of 5 prospective US cohorts found no association, regardless of CagA status (OR 0.83; 95% CI 0.65–1.06).[21]
- A 2025 meta-analysis found no significant overall association (OR 1.15; 95% CI 0.93–1.41).[22]
- Not currently an actionable risk factor.
- Alcohol as an independent cause — causal evidence remains incomplete because of confounding by smoking and pancreatitis.[5]
- Moderate-penetrance carriers without a family history — guidelines disagree on whether BRCA1, ATM, or PALB2 carriers without a family history of PDAC should be considered high risk for surveillance purposes.[17][10]
Clinical Implications of Risk Stratification
- Universal germline testing: Offer multigene panel germline testing to all patients diagnosed with PDAC, regardless of age or family history.[10][15]
- Relatives: Refer first-degree relatives for genetic counseling. Use cascade testing when a pathogenic variant is identified.[10]
- Screening: Screening unselected patients with diabetes or chronic pancreatitis is not supported, because absolute risk is too low. Enrichment by genotype, family history, or NOD phenotype is required.[3][6]
- NOD evaluation: Consider occult PDAC in adults ≥50 years with new diabetes plus unexplained weight loss or rapidly worsening glycemia.[6]
- Risk reduction: Counseling should prioritize smoking cessation, which carries the largest attributable benefit. Weight control, alcohol moderation, and metabolic optimization are also recommended.[4]
- Gene-specific surveillance eligibility and start ages are covered in Pancreatic cancer screening.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Park W, Chawla A, O'Reilly EM (2021). "Pancreatic Cancer: A Review". JAMA. 326 (9): 851–862. doi:10.1001/jama.2021.13027. PMID 34547082 Check
|pmid=value (help). - ↑ 2.0 2.1 2.2 2.3 2.4 Stoop TF, Javed AA, Oba A, Groot Koerkamp B, Seufferlein T; et al. (2025). "Pancreatic cancer". Lancet. doi:10.1016/S0140-6736(25)00261-2.
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 Stoffel EM, Brand RE, Goggins M (2023). "Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention". Gastroenterology. 164 (5): 752–765. doi:10.1053/j.gastro.2023.02.012. PMID 36804602 Check
|pmid=value (help). - ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 Roth S, Apte M, Balachandran VP, Biffi G, Conroy T; et al. (2026). "Pancreatic cancer". Nat Rev Dis Primers. 12 (1): 23. doi:10.1038/s41572-026-00699-6.
- ↑ 5.0 5.1 Stolzenberg-Solomon R (2026). "Is Heavy Alcohol Use Associated With Young-Onset Pancreatic Cancer?". J Clin Oncol. 44: 730–732.
- ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 Wood LD, Canto MI, Jaffee EM, Simeone DM (2022). "Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment". Gastroenterology. 163 (2): 386–402.e1. doi:10.1053/j.gastro.2022.03.056.
- ↑ Hee NKY, Lim QH, Khunti K, Ooi YG, Yen IW, Saad M, Ekinci EI, Li HY, Vethakkan SR, Chan JCN, Lim LL (2026). "Secondary causes of diabetes: a crossroad of endocrinology and oncology". Lancet Diabetes Endocrinol. doi:10.1016/S2213-8587(26)00027-6.
- ↑ Cho J, Scragg R, Petrov MS (2020). "Postpancreatitis Diabetes Confers Higher Risk for Pancreatic Cancer Than Type 2 Diabetes: Results From a Nationwide Cancer Registry". Diabetes Care. 43: 2106–2112. doi:10.2337/dc20-0207.
- ↑ Thierens NDE, Verdonk RC, Löhr JM, van Santvoort HC, Bouwense SAW, van Hooft JE (2024). "Chronic pancreatitis". Lancet. 404 (10471): 2605–2618. PMID 39647500 Check
|pmid=value (help). - ↑ 10.0 10.1 10.2 10.3 National Comprehensive Cancer Network (2026). "NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Version 2.2026".
- ↑ 11.0 11.1 Hamada T, Yuan C, Yurgelun MB; et al. (2019). "Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk". Br J Cancer. doi:10.1038/s41416-019-0426-5.
- ↑ 12.0 12.1 Risch HA, Yu H, Lu L, Kidd MS (2010). "ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study". J Natl Cancer Inst. 102 (7): 502–505. doi:10.1093/jnci/djq007. PMID 20181960.
- ↑ 13.0 13.1 Yuan C, Kim J, Wang QL; et al. (2022). "The age-dependent association of risk factors with pancreatic cancer". Ann Oncol. 33 (7): 693–701. doi:10.1016/j.annonc.2022.03.276. PMID 35398288 Check
|pmid=value (help). - ↑ Grewal US, Patel RR, Loeffler BT; et al. (2026). "Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient survey". Cancer. 132 (10): e70446.
- ↑ 15.0 15.1 15.2 Stoffel EM, McKernin SE, Brand R; et al. (2019). "Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion". J Clin Oncol. 37 (2): 153–164. doi:10.1200/JCO.18.01489.
- ↑ Mizrahi JD, Surana R, Valle JW, Shroff RT (2020). "Pancreatic cancer". Lancet. 395 (10242): 2008–2020. doi:10.1016/S0140-6736(20)30974-0.
- ↑ 17.0 17.1 Monahan K, Hampel H, Stoffel E, Kupfer SS (2025). "In Our Scope of Practice: Genetic Risk Assessment and Testing for Gastrointestinal Cancers and Polyposis in Gastroenterology". Gastroenterology. 169 (6): 1147–1165. PMID 40484140 Check
|pmid=value (help). - ↑ Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011). "Pancreatic cancer". Lancet. 378: 607–620.
- ↑ 19.0 19.1 Jayakrishnan T, Ng K (2025). "Early-Onset Gastrointestinal Cancers: A Review". JAMA. doi:10.1001/jama.2025.10218. PMID 40674064 Check
|pmid=value (help). - ↑ 20.0 20.1 McWilliams RR, Maisonneuve P, Bamlet WR; et al. (2016). "Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis". Pancreas. 45 (2): 311–316. doi:10.1097/MPA.0000000000000392.
- ↑ Lee AA, Wang QL, Kim J, Babic A, Zhang X; et al. (2023). "Helicobacter pylori Seropositivity, ABO Blood Type, and Pancreatic Cancer Risk From 5 Prospective Cohorts". Clin Transl Gastroenterol. 14 (5): e00573. doi:10.14309/ctg.0000000000000573.
- ↑ Qin C; et al. (2025). "A study of the association between Helicobacter pylori infection type and pancreatic cancer risk: A systematic review and meta-analysis". Oncol Lett. doi:10.3892/ol.2025.14920.